1) Funatsu H, Yamashita H.
Pathophysiology of Diabetic Retinopathy.
Drug News Perspect. 2002 Dec;15(10):633-639.

2. Kohner EM, Patel V, Rassam SM.
Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy.
Diabetes. 1995 Jun;44(6):603-7. Review.

3. Wong TY, Klein R, Duncan BB, Nieto FJ, Klein BE, Couper DJ, Hubbard LD,
Sharrett AR. Racial Differences in the Prevalence of Hypertensive Retinopathy.
Hypertension. 2003 Mar 24

4. Chatterjee S, Chattopadhyay S, Hope-Ross M, Lip PL, Chattopadhya S.
Hypertension and the eye: changing perspectives.
J Hum Hypertens. 2002 Oct;16(10):667-75. Review.

5. Hyman BN.
The Eye as a Target Organ: An Updated Classification of Hypertensive
Retinopathy. J Clin Hypertens (Greenwich). 2000 May;2(3):194-197.

6. Sayag D, Gotzamanis A, Brugniart C, Segal A, Ducasse A, Chambre V,
Glacet-Bernard A. [Retinal vein occlusion and carotid Doppler imaging]
J Fr Ophtalmol. 2002 Oct;25(8):826-30. French.

7. Ueda Y, Kanazawa S, Ohira A, Miyamura N, Takaki T, Kitaoka T, Amemiya T.
Retinal vascular obstruction and asymptomatic cerebral infarction.
Jpn J Ophthalmol. 2002 Mar-Apr;46(2):209-14.

8. Recchia FM, Brown GC.
Systemic disorders associated with retinal vascular occlusion.
Curr Opin Ophthalmol. 2000 Dec;11(6):462-7. Review.

9. Bhagat N, Goldberg MF, Gascon P, Bell W, Haberman J, Zarbin MA.
Central retinal vein occlusion: review of management.
Eur J Ophthalmol. 1999 Jul-Sep;9(3):165-80. Review.

10. Wong VK.
Retinal venous occlusive disease.
Hawaii Med J. 1997 Oct;56(10):289-91. Review.

11. Laatikainen LT.
Management of retinal vein occlusion.
Curr Opin Ophthalmol. 1992 Jun;3(3):372-8. Review.

12. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin.
Am J Ophthalmol. 1994 Oct 15;118(4):421-9.

13. Agolini G, Cavallini GM.
[Long-term therapy of retinal vasculopathies with oral administration of high
doses of O-(beta-hydroxyethyl)-rutoside] Clin Ter. 1987 Jan 31;120(2):101-10.

14. Lumbroso Bruno
"Retinopatia Diabetica", pp 9-11, Casa Ed. ESAM Futura Roma, 1991. (modificata)

15. Incandela L, Cesarone MR, Cacchio M, De Sanctis MT, Santavenere C, D'Auro MG, Bucci M, Belcaro G.
Total triterpenic fraction of Centella asiatica in chronic venous insufficiency
and in high-perfusion microangiopathy.
Angiology. 2001 Oct; 52 Suppl 2:S9-13.

16. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Bavera P, Bucci M, Ippolito E.
Evaluation of treatment of diabetic microangiopathy with total triterpenic
fraction of Centella asiatica: a clinical prospective randomized trial with a
microcirculatory model.
Angiology. 2001 Oct;52 Suppl 2:S49-54.

17. Cesarone MR, Incandela L, De Sanctis MT, Belcaro G, Geroulakos G, Griffin M, Lennox A, Di Renzo AD, Cacchio M, Bucci M.
Flight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiatica. Angiology. 2001 Oct;52 Suppl 2:S33-7.

18. Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Grimaldi R, Marelli C,
Belcaro G. [The microcirculatory activity of Centella asiatica in venous insufficiency. A double-blind study] Minerva Cardioangiol. 1994 Jun;42(6):299-304. Italian.

19. Cesarone MR, Laurora G, De Sanctis MT, Belcaro G.
[Activity of Centella asiatica in venous insufficiency] Minerva Cardioangiol. 1992 Apr;40(4):137-43. Italian.

20. Belcaro GV, Grimaldi R, Guidi G.
Improvement of capillary permeability in patients with venous hypertension
after treatment with TTFCA. Angiology. 1990 Jul;41(7):533-40.

21. Droy-Lefaix MT, Cluzel J, Menerath JM, Bonhomme B, Doly M.
Antioxidant effect of a Ginkgo biloba extract (EGb 761) on the retina.
Int J Tissue React. 1995;17(3):93-100.

22. Ellnain-Wojtaszek M, Kruczynski Z, Kasprzak J.
Investigation of the free radical scavenging activity of Ginkgo biloba L. leaves.
Fitoterapia. 2003 Feb;74(1-2):1-6.

23. Koltringer P, Langsteger W, Klima G, Reisecker F, Eber O.
[Hemorheologic effects of ginkgo biloba extract EGb 761. Dose-dependent effect of EGb 761 on microcirculation and viscoelasticity of blood]
Fortschr Med. 1993 Apr 10;111(10):170-2. German.

24. Shen L, Cui Y.
[Effects of the leaf of Ginkgo biloba L. extract on blood rheology in animals]
Zhongguo Zhong Yao Za Zhi. 1998 Oct;23(10):622-3, 640- inside back cover.

25. Pepe C, Rozza A, Veronesi G.
[The evaluation by video capillaroscopy of the efficacy of a Ginkgo biloba
extract with L-arginine and magnesium in the treatment of trophic lesions in
patients with stage-IV chronic obliterating arteriopathy] Minerva Cardioangiol. 1999 Jun; 47(6):223-30. Italian.

26. Lotz-Winter H.
On the pharmacology of bromelain: an update with special regard to animal
studies on dose-dependent effects. Planta Med. 1990 Jun;56(3):249-53. Review.

27. Taussig SJ, Yokoyama MM, Chinen A, Onari K, Yamakido M.
Bromelain: a proteolytic enzyme and its clinical application. A review.
Hiroshima J Med Sci. 1975 Sep;24(2-3):185-93. Review.

28. Erdinçler, D. S., Karakoç, Y et al
The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability.
Clinical Hemorheology 1996, Vol. 16, No. 3, pp. 271-276.

29. Venditti P, Masullo P, Di Meo S, Agnisola C.
Protection against ischemia-reperfusion induced oxidative stress by vitamin E
treatment. Arch Physiol Biochem. 1999 Feb;107(1):27-34.

30. Rose RC, Bode AM.
Biology of free radical scavengers: an evaluation of ascorbate.
FASEB J. 1993 Sep;7(12):1135-42. Review.

31. Retsky KL, Freeman MW, Frei B.
Ascorbic acid oxidation product(s) protect human low density lipoprotein
against atherogenic modification. Anti- rather than prooxidant activity of
vitamin C in the presence of transition metal ions.
J Biol Chem. 1993 Jan 15;268(2):1304-9.

32. Yasuo Oyama, Paul A. Fuchs et al.
Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca++-loaded brain neurons.
Brain Research 635 (1994) 125-129.

33. Schonlau F, Rohdewald P.
Pycnogenol for diabetic retinopathy. A review.
Int Ophthalmol. 2001;24 (3): 161-71.

34. Spadea L, Balestrazzi E.
Treatment of vascular retinopathies with Pycnogenol.
Phytother Res. 2001 May;15 (3): 219-23.

35. Packer L, Rimbach G, Virgili F.
Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol.
Free Radic Biol Med. 1999 Sep;27 (5-6): 704-24.

36. Rohdewald P.
Review: The French maritime pine bark extract (Pycnogenol).
Int J Clin Pharm Ther. 2002 (40): 158-168.

37. Cho KJ, Jun CH et al.
Inhibition mechanisms of bioflavonoids extracted from the bark of pinus maritima on the expression of proinflammatory cytokines.
Ann NY Acad Sci. 2001 (928): 141-156.